Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 18,688

Document Document Title
WO/2010/121324A1
The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and ...  
WO/2010/123243A2
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...  
WO/2010/123243A3
The present invention relates to a composition containing a testis extract for treating or preventing diseases. More particularly, a testis extract, which is a natural substance obtained by separating sex hormones containing anabolic ste...  
WO/2010/119875A1
Disclosed is a fused pyrrolopyridine derivative which is useful as an active ingredient for a pharmaceutical composition, in particular a pharmaceutical composition for prevention or treatment of diseases that are caused by undesirable c...  
WO/2010/118675A1
The present invention reveals a new use of neferine. Neferine regulates M8 and V1 subtype of transient receptor potential ion channel (TRPM8 and TRPV1), respectively, in mammals, including humans, and can be used for preparing medicament...  
WO/2010/118699A1
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.  
WO/2010/121225A2
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...  
WO/2010/121225A3
The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compo...  
WO/2010/116673A1
Disclosed are a novel mitochondrial function-improving agent and a novel PGC-1α expression inducer. Specifically disclosed are a mitochondrial function-improving agent and a PGC-1α expression inducer, each of which comprises a lysine-s...  
WO/2010/113225A1
The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Fur...  
WO/2010/112093A1
Compounds of formula (I), wherein R1, R2, R3, X and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112091A1
Compounds of formula (I) wherein R1, R2, R3, X, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112092A1
Compounds of formula (I) wherein R1, R2, R3, R4, L1, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/113834A1
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...  
WO2010110440A1
Disclosed is a prophylactic and/or therapeutic agent for cognitive impairment including dementia of the Alzheimer type, which comprises 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)- 1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid ...  
WO/2010/109386A1
The invention relates to a method for the industrial purification of biologically active phyctotoxins. According to said method, an adequate quantity of a phycotoxin source is provided; if the source of phycotoxins is a pellet, it is lys...  
WO/2010/108843A1
The present invention relates to the use of nitric oxide releasing derivatives of paracetamol for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.  
WO/2010/108001A3
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/108001A2
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/106295A1
The invention relates to decorin for increasing muscle mass, in particular in the treatment of muscular dystrophies.  
WO/2010/104024A1
Disclosed is a piperazine compound represented by general formula (I) or a salt thereof. [In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents any one selected from a hydroxy group, an alkyl group having...  
WO/2010/095663A1
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a sub...  
WO/2010/092966A1
Disclosed is a novel compound having P2X3 or P2X2/3 receptor antagonistic effect. Specifically disclosed is a compound represented by formula (I). (In the formula, (a) Ra and Rb combine together to form =Z, and Rc is a group represented...  
WO/2010/093322A1
The present invention relates to methods for identifying therapeutic agents capable of modulating the activity of the IGF2 repressor ZBED6 for use in growth promotion,wound healing, angiogenesis, inhibition of muscle wasting, and treatme...  
WO/2010/093784A2
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/093784A3
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/087313A1
Disclosed is a novel neurite elongation stimulator. The neurite elongation stimulator comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represent a hydrogen a...  
WO/2010/086040A1
Compounds of formula (I) wherein R1, R2, R3, R4, R5, L1, L2, m, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/087244A1
A novel low-molecular compound having an immunosuppressive action. The compound is a compound having general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the substituents are defined as shown below: R1 and...  
WO/2010/087306A1
Disclosed is a novel anti-neurodegenerative disease agent. The anti-neurodegenerative disease agent comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represen...  
WO/2010/084999A1
Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases, which contain the substances (for example, anti-galectin-9 antibody, anti-Tim-3 antibody, RNA and DNA aptamers and low molecular substances) blocki...  
WO/2010/081862A3
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...  
WO/2010/081862A2
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...  
WO/2010/080581A2  
WO/2010/081070A2
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...  
WO/2010/081070A3
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...  
WO/2010/080455A1
This invention relates to a hydrochloride, malafe, oxalate and tartrate salt forms of 1-(4- { 1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl} -2-ethyl-benzyI)-azetidine- 3-carboxylic acid (Compound I), to pharmaceutical comp...  
WO/2010/079668A1
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R1, R2, R2', R4, R5, R6, R7, R8 and R8' each represents a hydrogen atom or the like; and R3 represents a hydrogen...  
WO/2010/075611A1
A composition comprising a proanthocyanidin, a proteolytic enzyme and a substance derived from Aloe Vera and/or from a plant of the Agave species, the composition being free of papain. Use of the composition for improving athletic perfor...  
WO/2010/077686A1
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...  
WO/2010/074284A1
By searching for a number of various compounds having an activity of inhibiting IL-12/IL-23 production, provided are a medicinal composition and a drug for treating or preventing a disease relating to the hyperproduction of IL-12/IL-23, ...  
WO/2010/075263A3
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...  
WO/2010/073531A1
Provided is a muscle-building agent comprising a whey protein hydrolyzate having a muscle increasing effect which is highly safe, an aqueous solution of which is highly transparent and which can be used in various products without limita...  
WO/2010/075287A3
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...  
WO/2010/075263A2
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...  
WO/2010/075287A2
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...  
WO/2010/071794A1
This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]- ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this c...  
WO/2010/069684A1
Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/069949A1
The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.  
WO/2010/070094A1
Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture...  

Matches 701 - 750 out of 18,688